

**Anti-LILRA4 / ILT7 / CD85g Reference Antibody (daxdilimab)
Recombinant Antibody
Catalog # APR10129****Specification**

Anti-LILRA4 / ILT7 / CD85g Reference Antibody (daxdilimab) - Product Information

| | |
|-------------------|------------------------|
| Application | FC, E, FTA |
| Primary Accession | P59901 |
| Reactivity | Cynomolgus, Human |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Calculated MW | 144.38 KDa |

Anti-LILRA4 / ILT7 / CD85g Reference Antibody (daxdilimab) - Additional Information**Target/Specificity**
LILRA4 / ILT7 / CD85g**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-LILRA4 / ILT7 / CD85g Reference Antibody (daxdilimab) - Protein Information****Name** LILRA4 ([HGNC:15503](#))**Function**

Functions coreceptor to limit the innate immune responses to viral infections; signaling occurs via FCER1G (PubMed:16735691, PubMed:19564354). Down-regulates the production of IFNA1, IFNA2, IFNA4, IFNB1 and TNF by plasmacytoid dendritic cells that have been exposed to influenza virus or cytidine-phosphate-guanosine (CpG) dinucleotides, indicating it functions as a negative regulator of TLR7 and TLR9 signaling cascades (PubMed:16735691, PubMed:19564354, PubMed:24586760). Down-regulates interferon production in response to interaction with BST2 on HIV-1 infected cells (PubMed:26172439).

Activates a signaling cascade in complex with FCER1G that results in phosphorylation of Src family and Syk kinases and thereby triggers mobilization of intracellular Ca²⁺ (PubMed:16735691, PubMed:19564354). Does not interfere with the differentiation of plasmacytoid dendritic cells into antigen-presenting cells (PubMed:24586760).

Cellular Location

Cell membrane; Single-pass type I membrane protein

Tissue Location


Detected on plasmacytoid dendritic cells (at protein level). Detected on plasmacytoid dendritic cells, but not on monocytes or B cells.

Anti-LILRA4 / ILT7 / CD85g Reference Antibody (daxdilimab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-LILRA4 / ILT7 / CD85g Reference Antibody (daxdilimab) - Images




Anti-LILRA4 / ILT7 / CD85g Reference Antibody (daxdilimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-LILRA4 / ILT7 / CD85g Reference Antibody (daxdilimab) is more than 96.58% ,determined by SEC-HPLC.



Immobilized human ILT7 His at 2 µg/mL can bind Anti-LILRA4 / ILT7 / CD85g Reference Antibody (daxdilimab) EC50=0.07254 µg/mL



Human ILT7 HEK293 cells were stained with Anti-LILRA4 / ILT7 / CD85g Reference Antibody (daxdilimab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC183=0.031 ug/mL